References
- Tintle S, Shemer A, Suárez-Fariñas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):1–14.
- Legartová S, Fagherazzi P, Goswami P, et al. Irradiation potentiates p53 phosphorylation and p53 binding to the promoter and coding region of the TP53 gene. Biochimie. 2023;204:154–168.
- Ahn K. The role of air pollutants in atopic dermatitis. J Allergy Clin Immunol. 2014;134(5):993–999; discussion 1000.
- Lonne-Rahm S, Sundström I, Nordlind K, et al. Adult Atopic dermatitis patients and physical exercise: a swedish questionnaire study. Acta Derm Venereol. 2014;94(2):185–187.
- Hu S, Anand P, Laughter M, et al. Holistic dermatology: an evidence-based review of modifiable lifestyle factor associations with dermatologic disorders. J Am Acad Dermatol. 2022;86(4):868–877.
- Hurd PJ. The era of epigenetics. Brief Funct Genomics. 2010;9(5–6):425–428.
- Cantara WA, Crain PF, Rozenski J, et al. The RNA modification database, RNAMDB: 2011 update. Nucleic Acids Res. 2011;39(Database issue):D195–D201.
- Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive Analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149(7):1635–1646.
- Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–3975.
- Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Res. 1975;2(10):1653–1668.
- Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887.
- Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206.
- Zhang H, Shi X, Huang T, et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–6264.
- Chen T, Hao YJ, Zhang Y, et al. m(6)a RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16(3):289–301.
- Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63(2):306–317.
- Liu J, Yue Y, Han D, et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93–95.
- Śledź P, Jinek M. Structural insights into the molecular mechanism of the m6A writer complex. eLife. 2016;5:e18434.
- Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–189.
- Schwartz S, Agarwala SD, Mumbach MR, et al. High-Resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell. 2013;155(6):1409–1421.
- Horiuchi K, Kawamura T, Iwanari H, et al. Identification of wilms’ tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J Biol Chem. 2013;288(46):33292–33302.
- Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.
- Pendleton KE, Chen B, Liu K, et al. The U6 snRNA m 6 a methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(5):824–835.e14.
- Wen J, Lv R, Ma H, et al. Zc3h13 Regulates nuclear RNA m6A methylation and mouse embryonic stem cell Self-Renewal. Mol Cell. 2018;69(6):1028–1038.e6.
- Ma H, Wang X, Cai J, et al. N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat Chem Biol. 2019;15(1):88–94.
- Patil DP, Chen C, Pickering BF, et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–373.
- Růžička K, Zhang M, Campilho A, et al. Identification of factors required for m(6) a mRNA methylation in arabidopsis reveals a role for the conserved E3 ubiquitin ligase HAKAI. New Phytol. 2017;215(1):157–172.
- Wang Y, Zhang L, Ren H, et al. Role of hakai in m6A modification pathway in drosophila. Nat Commun. 2021;12(1):2159.
- Church C, Moir L, McMurray F, et al. Overexpression of fto leads to increased food intake and results in obesity. Nat Genet. 2010;42(12):1086–1092.
- Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894.
- Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24(12):1403–1419.
- Wei J, Liu F, Lu Z, et al. Differential m(6)A, m(6)A(m), and m(1)a demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 2018;71(6):973–985.e5.
- Fu Y, Jia G, Pang X, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798.
- Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29.
- Liu N, Zhou KI, Parisien M, et al. N 6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017;45(10):6051–6063.
- Liu N, Dai Q, Zheng G, et al. N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. Nature. 2015;518(7540):560–564.
- Theler D, Dominguez C, Blatter M, et al. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. Nucleic Acids Res. 2014;42(22):13911–13919.
- Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315–328.
- Ries RJ, Zaccara S, Klein P, et al. m(6)a enhances the phase separation potential of mRNA. Nature. 2019;571(7765):424–428.
- Zhang Z, Luo K, Zou Z, et al. Genetic analyses support the contribution of mRNA N(6)-methyladenosine (m(6)A) modification to human disease heritability. Nat Genet. 2020;52(9):939–949.
- Lin S, Choe J, Du P, et al. The m 6 a methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62(3):335–345.
- Mendel M, Delaney K, Pandey RR, et al. Splice site m6A methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell. 2021;184(12):3125–3142.e25.
- Wang X, Zhao BS, Roundtree IA, et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6):1388–1399.
- Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120.
- Li A, Chen Y, Ping X, et al. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27(3):444–447.
- Xiao W, Adhikari S, Dahal U, et al. Nuclear m 6 a reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61(4):507–519.
- Roundtree IA, Luo G, Zhang Z, et al. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. eLife. 2017;6:e31311.
- Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–1127.
- Alarcón CR, Goodarzi H, Lee H, et al. HNRNPA2B1 is a mediator of m6A-Dependent nuclear RNA processing events. Cell. 2015;162(6):1299–1308.
- Cieniková Z, Damberger FF, Hall J, et al. Structural and mechanistic insights into poly(uridine) tract recognition by the hnRNP C RNA recognition motif. J Am Chem Soc. 2014;136(41):14536–14544.
- Mccloskey A, Taniguchi I, Shinmyozu K, et al. hnRNP C tetramer measures RNA length to classify RNA polymerase II transcripts for export. Science. 2012;335(6076):1643–1646.
- Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–295.
- Wu R, Li A, Sun B, et al. A novel m6A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res. 2019;29(1):23–41.
- Zhang F, Kang Y, Wang M, et al. Fragile X mental retardation protein modulates the stability of its m6A-marked messenger RNA targets. Hum Mol Genet. 2018:27–22.
- Edupuganti VSRR, Geiger S, Lindeboom RGH, et al. N6-methyladenosine (m6A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol. 2017;24(10):870–878.
- Meyer KD, Patil DP, Zhou J, et al. 5′ UTR m6A promotes cap-independent translation. Cell. 2015;163(4):999–1010.
- Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014;8(1):284–296.
- Wang Y, Wang J, Gao L, et al. An SRp75/hnRNPG complex interacting with hnRNPE2 regulates the 5′ splice site of tau exon 10, whose misregulation causes frontotemporal dementia. Gene. 2011;485(2):130–138.
- Xu C, Wang X, Liu K, et al. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Nat Chem Biol. 2014;10(11):927–929.
- Berulava T, Rahmann S, Rademacher K, et al. N6-adenosine methylation in MiRNAs. PLoS One. 2015;10(2):e118438.
- Alarcón CR, Lee H, Goodarzi H, et al. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519(7544):482–485.
- Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626–641.
- Wang Y, Li Y, Toth JI, et al. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191–198.
- Batista PJ, Molinie B, Wang J, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15(6):707–719.
- Geula S, Moshitch-Moshkovitz S, Dominissini D, et al. m6 a mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015;347(6225):1002–1006.
- Xi L, Carroll T, Matos I, et al. m6A RNA methylation impacts fate choices during skin morphogenesis. eLife. 2020;9:e56980.
- Ear J, Lin S. RNA methylation regulates hematopoietic stem and progenitor cell development. J Genet Genomics. 2017;44(10):473–474.
- Lin Z, Hsu PJ, Xing X, et al. Mettl3-/Mettl14-mediated mRNA N(6)-methyladenosine modulates murine spermatogenesis. Cell Res. 2017;27(10):1216–1230.
- Ivanova I, Much C, Di Giacomo M, et al. The RNA m 6 a reader YTHDF2 is essential for the post-transcriptional regulation of the maternal transcriptome and oocyte competence. Mol Cell. 2017;67(6):1059–1067.e4.
- Gao X, Shin Y, Li M, et al. The Fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One. 2010;5(11):e14005.
- McTaggart JS, Lee S, Iberl M, et al. FTO is expressed in neurones throughout the brain and its expression is unaltered by fasting. PLoS One. 2011;6(11):e27968.
- Li L, Zang L, Zhang F, et al. Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Hum Mol Genet. 2017;26(13):2398–2411.
- Wang C, Cui G, Liu X, et al. METTL3-mediated m6A modification is required for cerebellar development. PLoS Biol. 2018;16(6):e2004880.
- Yoon K, Ringeling FR, Vissers C, et al. Temporal control of mammalian cortical neurogenesis by m6A methylation. Cell. 2017;171(4):877–889.e17.
- Ma C, Chang M, Lv H, et al. RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum. Genome Biol. 2018;19(1):68.
- Lizama CO, Hawkins JS, Schmitt CE, et al. Repression of arterial genes in hemogenic endothelium is sufficient for haematopoietic fate acquisition. Nat Commun. 2015;6:7739.
- Zhang C, Chen Y, Sun B, et al. m(6)a modulates haematopoietic stem and progenitor cell specification. Nature. 2017;549(7671):273–276.
- Mapperley C, van de Lagemaat LN, Lawson H, et al. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. J Exp Med. 2021;218(3):e20200829.
- Gao Y, Vasic R, Song Y, et al. m(6)a modification prevents formation of endogenous Double-Stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity. 2020;52(6):1007–1021.e8.
- Vu LP, Pickering BF, Cheng Y, et al. The N(6)-methyladenosine (m(6)a)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369–1376.
- Wang H, Zuo H, Liu J, et al. Loss of YTHDF2-mediated m(6)A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration. Cell Res. 2018;28(10):1035–1038.
- Wang H, Hu X, Huang M, et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat Commun. 2019;10(1):1898.
- Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–274.
- Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–795.
- Liu Z, Ma Y, Cui Q, et al. Toll-like receptor 4 plays a key role in advanced glycation end products-induced M1 macrophage polarization. Biochem Biophys Res Commun. 2020;531(4):602–608.
- Tong J, Wang X, Liu Y, et al. Pooled CRISPR screening identifies m(6)a as a positive regulator of macrophage activation. Sci Adv. 2021;7(18):eabd4742.
- Gu X, Zhang Y, Li D, et al. N6-methyladenosine demethylase FTO promotes M1 and M2 macrophage activation. Cell Signal. 2020;69:109553.
- Dong L, Chen C, Zhang Y, et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell. 2021;39(7):945–957.e10.
- Li H, Tong J, Zhu S, et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338–342.
- Tong J, Cao G, Zhang T, et al. m6A mRNA methylation sustains treg suppressive functions. Cell Res. 2018;28(2):253–256.
- Zhu Y, Zhao Y, Zou L, et al. The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control. J Exp Med. 2019;216(7):1664–1681.
- Ding C, Xu H, Yu Z, et al. RNA m(6)a demethylase ALKBH5 regulates the development of γδ T cells. Proc Natl Acad Sci U S A. 2022;119(33):e2091649177.
- Zhou J, Zhang X, Hu J, et al. m(6)a demethylase ALKBH5 controls CD4(+) T cell pathogenicity and promotes autoimmunity. Sci Adv. 2021;7(25):eabg0470.
- Zheng Z, Zhang L, Cui X, et al. Control of early B cell development by the RNA N6-Methyladenosine methylation. Cell Rep. 2020;31(13):107819.
- Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res. 2014;20(8):2044–2050.
- Song H, Song J, Cheng M, et al. METTL3-mediated m(6)a RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12(1):5522.
- Ma S, Yan J, Barr T, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J Exp Med. 2021;218(8):e20210279.
- Luo Q, Fu B, Zhang L, et al. Decreased Peripheral blood ALKBH5 correlates with markers of autoimmune response in systemic lupus erythematosus. Dis Markers. 2020;2020:1–11.
- Luo Q, Rao J, Zhang L, et al. The study of METTL14, ALKBH5, andYTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus. Mol Genet Genomic Med. 2020;8(9):e1298.
- Wang Y, Jin H. Transcriptome-Wide m6A methylation in skin lesions from patients with psoriasis vulgaris. Front Cell Dev Biol. 2020;8:591629.
- Zhao T, Sun D, Zhao M, et al. N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut. 2020;259:113908.
- Dahal U, Le K, Gupta M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019;29(4):382–389.
- Yue Z, Cao M, Hong A, et al. m(6)a methyltransferase METTL3 promotes the progression of primary acral melanoma via mediating TXNDC5 methylation. Front Oncol. 2021;11:770325.
- Yang S, Wei J, Cui Y, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782.
- Jia R, Chai P, Wang S, et al. m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18(1):161.
- Xu Y, He X, Wang S, et al. The m(6)a reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation. Oncogene. 2022;41(9):1281–1297.
- Zhou R, Gao Y, Lv D, et al. METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ΔNp63. Biochem Biophys Res Commun. 2019;515(2):310–317.
- Orouji E, Peitsch WK, Orouji A, et al. Oncogenic Role of an epigenetic reader of m(6)a RNA modification: YTHDF1 in merkel cell carcinoma. Cancers (Basel). 2020;12(1):202.
- Ye F, Chen ER, Nilsen TW. Kaposi’s Sarcoma-Associated herpesvirus utilizes and manipulates RNA N6-Adenosine methylation to promote lytic replication. J Virol. 2017;91(16):e00466–17.
- Llabjani V, Hoti V, Pouran HM, et al. Bimodal responses of cells to trace elements: insights into their mechanism of action using a biospectroscopy approach. Chemosphere. 2014;112:377–384.
- Chen H, Zhao T, Sun D, et al. Changes of RNA N6-methyladenosine in the hormesis effect induced by arsenite on human keratinocyte cells. Toxicol in Vitro. 2019;56:84–92.
- Cayir A, Barrow TM, Guo L, et al. Exposure to environmental toxicants reduces global N6-methyladenosine RNA methylation and alters expression of RNA methylation modulator genes. Environ Res. 2019;175:228–234.
- Zhao T, Li X, Sun D, et al. Oxidative stress: one potential factor for arsenite-induced increase of N6-methyladenosine in human keratinocytes. Environ Toxicol Pharmacol. 2019;69:95–103.
- Jiang L, Hickman JH, Wang S, et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle. 2015;14(18):2881–2885.
- Gu S, Sun D, Dai H, et al. N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells. Toxicol Lett. 2018;292:1–11.
- Bai L, Tang Q, Zou Z, et al. m6A demethylase FTO regulates dopaminergic neurotransmission deficits caused by arsenite. Toxicol Sci. 2018;165(2):431–446.
- Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605–614.
- Zhang B, Zhou T, Wu H, et al. Difference of IFI44L methylation and serum IFN-a1 level among patients with discoid and systemic lupus erythematosus and healthy individuals. J Transl Autoimmun. 2021;4:100092.
- Zhang B, Liu L, Zhou T, et al. A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus. Clin Immunol. 2020;221:108612.
- Hong Y, Wu J, Zhao J, et al. miR-29b and miR-29c are involved in Toll-Like receptor control of Glucocorticoid-Induced apoptosis in human plasmacytoid dendritic cells. PLoS One. 2013;8(7):e69926.
- Chafin CB, Regna NL, Hammond SE, et al. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharmacol. 2013;17(3):894–906.
- Li L, Fan Y, Leng R, et al. Potential link between m 6 a modification and systemic lupus erythematosus. Mol Immunol. 2018;93:55–63.
- Sun HL, Zhu AC, Gao Y, et al. Stabilization of ERK-Phosphorylated METTL3 by USP5 increases m(6)a methylation. Mol Cell. 2020;80(4):633–647.
- Xiong J, He J, Zhu J, et al. Lactylation-driven METTL3-mediated RNA m(6)a modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82(9):1660–1677.e10.
- Deng J, Zhang J, Ye Y, et al. N(6) -methyladenosine-Mediated upregulation of WTAPP1 promotes WTAP translation and wnt signaling to facilitate pancreatic cancer progression. Cancer Res. 2021;81(20):5268–5283.
- Cho S, Lee G, Pickering BF, et al. mTORC1 promotes cell growth via m(6)A-dependent mRNA degradation. Mol Cell. 2021;81(10):2064–2075.e8.
- Han H, Fan G, Song S, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021;137(12):1603–1614.
- Zhang D, Ning J, Okon I, et al. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer. Cell Death Dis. 2021;12(6):518.
- Yue C, Chen J, Li Z, et al. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis. J Exp Clin Cancer Res. 2020;39(1):240.
- Yang X, Shao F, Guo D, et al. WNT/β-catenin-suppressed FTO expression increases m(6)a of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death Dis. 2021;12(5):462.
- Yu J, Chai P, Xie M, et al. Histone lactylation drives oncogenesis by facilitating m(6)a reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22(1):85.
- Fang R, Chen X, Zhang S, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177.
- Zhao X, Ge L, Wang J, et al. Exploration of potential integrated models of N6-Methyladenosine immunity in systemic lupus erythematosus by bioinformatic analyses. Front Immunol. 2021;12:752736.
- Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
- Liu J, Thatiparthi A, Martin A, et al. Prevalence of psoriasis among adults in the U.S. 2009-2010 and 2013-2014 national health and nutrition examination surveys. J Am Acad Dermatol. 2021;84(3):767–769.
- Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. Exp Dermatol. 2021;30(8):1156–1166.
- Xian J, Shang M, Dai Y, et al. N(6)-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p/AKT3 axis. J Dermatol Sci. 2022;105(1):27–36.
- Rahib L, Wehner MR, Matrisian LM, et al. Estimated Projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.
- Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3–eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556–560.
- Zheng W, Li Y, Su Z, et al. EIF3H knockdown inhibits malignant melanoma through regulating cell proliferation, apoptosis and cell cycle. Exp Cell Res. 2021;402(1):112488.
- Lin Y, Wang S, Liu S, et al. Identification and verification of molecular subtypes with enhanced immune infiltration based on m6A regulators in cutaneous melanoma. Biomed Res Int. 2021;2021:1–19.
- Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(2):237–247.
- Mbbf A, Dmh B, Jin Q, et al. Merkel cell carcinoma incidence, trends, and survival rates among adults aged ≥50years from United States cancer Statistics - ScienceDirect. J Am Acad Dermatol. 2019;80(4):1154–1156.
- Mamimandjiami AI, Mouinga-Ondémé A, Ramassamy J, et al. Epidemiology and genetic variability of HHV-8/KSHV among rural populations and kaposi’s sarcoma patients in Gabon, Central africa. Review of the geographical distribution of HHV-8 K1 genotypes in Africa. Viruses. 2021;13(2):175.
- Ye F. RNA N-adenosine methylation (mA) steers epitranscriptomic control of herpesvirus replication. Inflammation Cell Signaling. 2017;4(3):e1604.
- Selberg S, Blokhina D, Aatonen M, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site. Cell Rep. 2019;26(13):3762–3771.e5.
- Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601.
- Xu QC, Tien YC, Shi YH, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner. Oncogene. 2022;41(11):1622–1633.
- Zhang ZW, Teng X, Zhao F, et al. METTL3 regulates m(6)a methylation of PTCH1 and GLI2 in sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma. Cell Rep. 2022;41(4):111530.
- Bedi RK, Huang D, Eberle SA, et al. Small-Molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem. 2020;15(9):744–748.
- He Y, Wang W, Xu X, et al. Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)a modification. Bone. 2022;154:116182.
- Wang JN, Wang F, Ke J, et al. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms. Sci Transl Med. 2022;14(640):k2709.
- Huang Y, Su R, Sheng Y, et al. Small-Molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(4):677–691.e10.
- Liu Y, Liang G, Xu H, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33(6):1221–1233.e11.
- Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79–96.e11.
- Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)a/MYC/CEBPA signaling. Cell. 2018;172(1–2):90–105.e23.
- He W, Zhou B, Liu W, et al. Identification of a novel Small-Molecule binding site of the fat mass and obesity associated protein (FTO). J Med Chem. 2015;58(18):7341–7348.
- Qiao Y, Zhou B, Zhang M, et al. A novel inhibitor of the obesity-related protein FTO. Biochemistry. 2016;55(10):1516–1522.
- Zhou P, Wu M, Ye C, et al. Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m(6)a abrogation in RNA. J Biol Chem. 2019;294(45):16908–16917.
- Xiao L, Li X, Mu Z, et al. FTO Inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma. Cancer Res. 2020;80(18):3945–3958.
- Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA. 2020;117(33):20159–20170.
- Müller S, Bley N, Busch B, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 2020;48(15):8576–8590.
- Mahapatra L, Andruska N, Mao C, et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl Oncol. 2017;10(5):818–827.